United Kingdom

Evox Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Evox Therapeutics Expands Existing Exosome Patent Portfolio With Further Grant Covering Exosomes for RNA Therapeutics

Lead Product(s): Exosome-mediated RNAi

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 15, 2020

Details:

The recently issued US patent provides broad coverage for pharmaceutical compositions comprising exosomes containing nucleic acid-based therapeutics, such as RNAi agents and antisense oligonucleotides, which have been loaded by electroporation.

Evox Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Evox Therapeutics Announces a Multi-target RNAi and Antisense Research Collaboration and License Agreement With Lilly

Lead Product(s): RNA interference

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Eli Lilly

Deal Size: $1,230‬.0 million Upfront Cash: $20.0 million

Deal Type: Licensing Agreement June 09, 2020

Details:

During this research collaboration and five-target license agreement, Evox will be responsible for exosome engineering in order to achieve brain/CNS-targeting, drug loading and analytics and some in vitro assay development, as well as material supply for initial in vivo studies.

Concept Life Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

AstronauTx Announces an Alliance With Concept Life Sciences to Accelerate the Identification of Novel Therapies For Alzheimer's Disease

Lead Product(s): Undisclosed

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: AstronauTx

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 02, 2020

Details:

The alliance will focus on identifying small molecule drugs able to modulate astrocyte biology to expand AstronauTx's pipeline of novel therapeutic candidates for the treatment of Alzheimer's disease.

Icagen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Ligand Announces Icagen’s Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases

Lead Product(s): Undisclosed

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

Deal Size: $274.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration May 29, 2020

Details:

Collaboration initiates second Roche program utilizing Icagen’s ion channel drug discovery platform.

Almac Group

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Merck Taps Almac in Neurodegenerative Drug Discovery Deal

Lead Product(s): Undisclosed

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: Merck & Co. Inc.

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 29, 2020

Details:

Research collaboration will focus on developing new small molecule inhibitors against specific targets of Deubiquitinase to treat a variety of neurodegenerative and other diseases.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Evox Therapeutics

Evox Therapeutics Expands Existing Exosome Patent Portfolio With Further Grant Covering Exosomes for RNA Therapeutics

Evox Therapeutics

Evox Therapeutics Announces a Multi-target RNAi and Antisense Research Collaboration and License Agreement With Lilly

Concept Life Sciences

AstronauTx Announces an Alliance With Concept Life Sciences to Accelerate the Identification of Novel Therapies For Alzheimer's Disease

Icagen

Ligand Announces Icagen’s Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases

Almac Group

Merck Taps Almac in Neurodegenerative Drug Discovery Deal